Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?

Niki Karachaliou^{1

2}, Manuel Fernandez-Bruno¹, Rafael Rosell^{2

3

4

5}

Affiliations

¹ Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, QuironSalud Group, Barcelona, Spain.
² Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain.
³ Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain.
⁴ Catalan Institute of Oncology, Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain.
⁵ Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain.

Editorial

Niki Karachaliou et al. Transl Lung Cancer Res. 2018 Sep.

. 2018 Sep;7(Suppl 3):S198-S201.

doi: 10.21037/tlcr.2018.07.02.

Niki Karachaliou^{1

2}, Manuel Fernandez-Bruno¹, Rafael Rosell^{2

3

4

5}

¹ Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, QuironSalud Group, Barcelona, Spain.
² Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain.
³ Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain.
⁴ Catalan Institute of Oncology, Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain.
⁵ Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

1. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015;16:763-74. 10.1016/S1470-2045(15)00021-2 - DOI - PubMed
1. Karachaliou N, Rosell R. Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges. Ther Adv Med Oncol 2018;10:1758835918763723. 10.1177/1758835918763723 - DOI - PMC - PubMed
1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28. 10.1056/NEJMoa1501824 - DOI - PubMed
1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7 - DOI - PubMed
1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed